
ABSTRACT Traditional two‐dimensional (2D) cell cultures and avascular three‐dimensional (3D) skin models inadequately recapitulate the vascular architecture, cellular interactions and physiological complexity of native human skin, limiting their ability to accurately model tissue repair, disease progression and therapeutic responses. This review comprehensively examines the current status of the 3D skin models, the rationale for vascularized models, cellular, biomaterial and scaffold design considerations, strategies to obtain vascularized models and their applications for wound healing, inflammatory and autoimmune skin diseases, skin cancer and drug, cosmetic and toxicity testing. We further highlight that closing the gap between the complex, appendage‐associated vascular architecture of native skin and the simplified networks currently achievable in engineered constructs, while improving reproducibility and standardization, will be critical for translating vascularized 3D skin models into robust clinical and industrial platforms.
ABSTRACT Chronic spontaneous urticaria (CSU) is a common, distressing skin disease driven by dysregulated immune responses. OX40 is a key costimulatory molecule implicated in Type 2 inflammation, yet the role of memory T cell subsets and the OX40/OX40L co‐stimulatory axis in driving CSU pathogenesis remains poorly defined. To characterize the peripheral frequencies of memory T cell subsets and OX40 expression patterns in patients with CSU, and to explore their associations with disease activity and autoimmune features, this study comprised two parts. Part 1 was a retrospective cohort analysis including 110 patients with CSU, examining the relationship between memory T‐cell subset frequencies and clinical parameters. Part 2 was a prospective nested case–control study including 30 age‐ and sex‐matched CSU patients (overlapping with Part 1) and 30 healthy controls (HCs), utilizing flow cytometry to assess OX40 expression on T‐cell subsets. Memory T cell subsets (naïve, central memory [TCM], effector memory [TEM]) and the percentages of OX40‐positive cells were analysed by flow cytometry. Key clinical parameters, including disease activity (7‐day Urticaria Activity Score, UAS7), health‐related quality of life (Dermatology Life Quality Index, DLQI), and thyroid autoantibody levels, were evaluated. CSU patients showed an imbalanced memory T cell profile, with increased frequencies of CD4 + TEM and reduced frequencies of CD4 + TCM. The percentage of OX40‐positive cells was significantly elevated on CD4 + TCM in CSU compared with HCs ( p = 0.005) and positively correlated with disease severity (UAS7: r s = 0.574, p = 0.001), impaired health‐related quality of life (DLQI: r s = 0.889, p < 0.001), and serum levels of thyroid peroxidase antibodies (TPOAb: r s = 0.418, p = 0.03). Our findings reveal dysregulated OX40 expression on memory T cells in CSU, linking it to disease severity and autoimmune features, thus identifying OX40 as a promising novel therapeutic target for patients with refractory CSU, especially those with autoimmune comorbidities.
ABSTRACT Deep neural networks classify dermoscopic and clinical images of skin lesions with accuracy that matches, and in curated comparisons exceeds, experienced dermatologists. Regulators have responded: an elastic scattering spectroscopy device with an embedded classifier is authorised for primary care in the United States, an image‐based system has conditional approval in the National Health Service, and consumer applications are marketed directly to the public. In this Viewpoint we argue that clinical deployment is advancing faster than the experimental evidence that investigative dermatology would normally demand. Performance measured on internal test sets falls when algorithms are exposed to external images, non‐dermoscopic photographs or other populations. Networks learn confounders, such as surgical ink markings, as readily as morphology, and the histopathological reference standard is itself subject to substantial observer variation. Public training datasets record skin phototype for about 2% of images and contain almost no darkest‐phototype, acral or nail images. Regulated devices with prospective evidence achieve high sensitivity or negative predictive value at the cost of low specificity, shifting referral and biopsy rates with unmeasured effects on patient outcomes and overdiagnosis, and the single randomised trial to date improved diagnostic accuracy, chiefly among non‐dermatologists, without measuring those outcomes. We identify where the largest gains lie, in primary care, allied health and under‐served regions, and propose an experimental agenda: phototype‐stratified external validation, shortcut‐detection and counterfactual explanation studies, consensus histopathological labelling, pragmatic randomised trials with outcome endpoints reported to CONSORT‐AI, and post‐market surveillance under the European Medical Device Regulation and Artificial Intelligence Act.
ABSTRACT The skin is a peripheral neuroimmunoendocrine organ that communicates bidirectionally with the central nervous system, providing a plausible biological basis for topical products intended to influence cutaneous sensation, physiological stress responses, or emotional well‐being. However, evidence supporting neurocosmetic claims remains heterogeneous, and biological mechanisms, peripheral physiological changes, and central or subjective outcomes are frequently conflated. Although previous reviews have described neurocosmetic ingredients, mechanisms, products, and neurophysiological assessment methods, an operational framework linking each claim type to its corresponding burden of proof remains lacking. This review critically evaluates the available evidence and proposes a unified, claim‐centred framework that organises neurocosmetic claims into three tiers—local cutaneous, peripheral physiological, and central or emotional—and aligns each tier with the evidence level required for substantiation. It also identifies suitable study designs and objective endpoints, mapping psychophysiological and neurophysiological methods—including salivary cortisol, heart‐rate variability, electrodermal activity, facial electromyography, EEG, fMRI, and MEG—to the specific types of claims they best support. Selected studies are then evaluated according to the correspondence between the claim, study design, comparator, and endpoint. Within the context of European cosmetic regulation, we argue that stronger claims require correspondingly stronger and more specific evidence. Current evidence most clearly supports local cutaneous effects, whereas many peripheral physiological and central or emotional effects require better‐controlled and adequately powered human studies. The proposed framework is intended to support more transparent, falsifiable, and proportionate substantiation of skin–brain claims.